Condition: Friedreich Ataxia · Cardiomyopathies · Cardiac Hypertrophy · Sponsor: Weill Medical College of Cornell University
The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 25 participants.
This description comes directly from the study's public registry record.
Maddie Galbraith, BS · 646-962-2672 · meg4013@med.cornell.edu
Niamh Savage, BS · 646-962-5527 · nis2049@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05302271